Business Description
Arbutus Biopharma Corp
NAICS : 325412
SIC : 3741
ISIN : CA03879J1003
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 71.27 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -5.42 | |||||
Beneish M-Score | -1.44 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.2 | |||||
3-Year EBITDA Growth Rate | 17.5 | |||||
3-Year EPS without NRI Growth Rate | 23.7 | |||||
3-Year FCF Growth Rate | 8.4 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 35.25 | |||||
9-Day RSI | 41.17 | |||||
14-Day RSI | 44.9 | |||||
6-1 Month Momentum % | 39.13 | |||||
12-1 Month Momentum % | 1.59 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.87 | |||||
Quick Ratio | 5.87 | |||||
Cash Ratio | 5.6 | |||||
Days Sales Outstanding | 42.56 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.2 | |||||
Shareholder Yield % | -6.07 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -430.15 | |||||
Net Margin % | -401.57 | |||||
FCF Margin % | -479.27 | |||||
ROE % | -56.84 | |||||
ROA % | -42.04 | |||||
ROIC % | -192.33 | |||||
ROC (Joel Greenblatt) % | -1099.75 | |||||
ROCE % | -48.97 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 24.36 | |||||
PB Ratio | 4.32 | |||||
Price-to-Tangible-Book | 4.32 | |||||
EV-to-EBIT | -4.95 | |||||
EV-to-EBITDA | -5.05 | |||||
EV-to-Revenue | 19.77 | |||||
EV-to-Forward-Revenue | 39.17 | |||||
EV-to-FCF | -4.15 | |||||
Price-to-Median-PS-Value | 1.18 | |||||
Price-to-Net-Current-Asset-Value | 4.87 | |||||
Price-to-Net-Cash | 5.15 | |||||
Earnings Yield (Greenblatt) % | -20.2 | |||||
FCF Yield % | -18.01 |